health technology assessment of Alemtuzumab (Lemtrada) compared to Natalizumab (Tysabri) in patients with relapsing-remitting multiple sclerosis

Cards: 1. On the basis of the ethical principles, the participants were fully informed of the study and written consent was obtained. 2. In case of adverse events, the study was stopped at the first signs of severe side effects.

Author: Dr. Rezaei Hooman

Address: rdaroudi@yahoo.com